Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
(NASDAQ: XENE) Delayed: 39.75 -17.6 (30.69%)
Previous Close $57.35    52 Week High $9.75 
Open $44.02    52 Week Low $5.65 
Day High $44.85    P/E N/A 
Day Low $39.08    EPS $0.00 
Volume 17,940,643       

(NASDAQ: XENE) Delayed: 39.75 -17.6 (30.69%)
Previous Close $57.35    52 Week High $9.75 
Open $44.02    52 Week Low $5.65 
Day High $44.85    P/E N/A 
Day Low $39.08    EPS $0.00 
Volume 17,940,643